书签 分享 收藏 举报 版权申诉 / 26
上传文档赚钱

类型早老性痴呆药物研究进展课件.ppt

  • 上传人(卖家):三亚风情
  • 文档编号:3419705
  • 上传时间:2022-08-29
  • 格式:PPT
  • 页数:26
  • 大小:675KB
  • 【下载声明】
    1. 本站全部试题类文档,若标题没写含答案,则无答案;标题注明含答案的文档,主观题也可能无答案。请谨慎下单,一旦售出,不予退换。
    2. 本站全部PPT文档均不含视频和音频,PPT中出现的音频或视频标识(或文字)仅表示流程,实际无音频或视频文件。请谨慎下单,一旦售出,不予退换。
    3. 本页资料《早老性痴呆药物研究进展课件.ppt》由用户(三亚风情)主动上传,其收益全归该用户。163文库仅提供信息存储空间,仅对该用户上传内容的表现方式做保护处理,对上传内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!
    4. 请根据预览情况,自愿下载本文。本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
    5. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007及以上版本和PDF阅读器,压缩文件请下载最新的WinRAR软件解压。
    配套讲稿:

    如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。

    特殊限制:

    部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。

    关 键  词:
    早老性 痴呆 药物 研究进展 课件
    资源描述:

    1、How to accelerate AD research 8/3/20222ContentsCurrent situation of AD1What are big companies doing 2Trends3Perspective48/3/202231 Current situation of ADvPopulation:37 million vCauses:too sophisticatedvMarket drugs:Tarcrine,Donepezil,Rivastigmine,Galanthamine,Huperzine,MemantinevSome social activit

    2、ies may correlate with AD,but cannot delay the progress of AD8/3/20224Nature Reviews.2010.7:387-3988/3/202252 What are big companies doingvA big cake attracts a lot of big companies,attention,such as Pfizer,Elan,Merk,Novartis and so on8/3/20226BMC Medicine 2009,7:7 8/3/20227TramiprosatevALZHEMED(Neu

    3、rochem Inc.)vThe Phase III trial did not show a beneficial effect on cognition or function,so the development program has been discontinued 8/3/20228Vaccines and antibodiesvAN-1792(Elan)the first-generation amyloid vaccine,Phase II trial was discontinued owing to the development of aseptic meningoen

    4、cephalitis in 6%of the patientsvACC-001(Elan)prevent the induction of a toxic cellular immune response,in a Phase II clinical trialvBapineuzumab(Elan/Wyeth):Phase III,monoclonal antibodiesvImmunoglobulin IgIV:Phase III,polyclonal antibodies8/3/202298/3/202210RAGE InhibitorvAmyloid is known to bind t

    5、o receptors for advanced glycated endproducts(RAGE)on the surface of cells and at the blood-brain barrier;this binding may contribute to inflammation and neuronal death.vPF-04494700:an orally bioavailable antagonist of RAGE,Phase II 8/3/202211-secretase inhibitorsvTarenflurbil:the enantiomer of the

    6、non-steroidal anti-inflammatory drug flurbiprofen,modulates the activity of-secretase,failed in Phase III vSemagacestat:reduction of amyloid peptide generation in blood and cerebrospinal fluid of patients with AD treated with tolerable doses,in Phase III8/3/202212Tau aggregation inhibitorvRember(Met

    7、hylene blue):a widely used histology dye,has been shown to interfere with tau aggregation.v Entering Phase III8/3/2022138/3/202214Microtubule stabilizervNAP(AL-108):derived from a natural neurotrophic protein,can be delivered to the central nervous system via intranasal administration.vmarkedly redu

    8、ces tau phosphorylation,and preliminary human studies have been encouraging.Now it is in Phase II trial.8/3/202215Dimebon-Pfizerv Phase III trial(Dimebon and Donepezil):failed,but Pfizer now is launching another Phase III trial about dimebon with other AD drugs.NNN8/3/202216vPhase III trials of Gink

    9、go biloba,NSAIDs,phenserine,statins,tarenflurbil,tramiprosate,and xaliproden have been completed,none of them demonstrating adequate efficacy.vPhase II trials of dimebon,huperzine A,intravenous immunoglobulin,and methylthioninium chloride were reported at 2008.vNineteen compounds are currently in Ph

    10、ase II trials,and 3 compounds(AN1792,lecozotan SR,and SGS742)failed at this stage of development.8/3/2022173 TrendsvMultitarget Anti-Alzheimer AgentsvAD modelvfurther explore the causesvcoalition and cooperation8/3/202218Multitarget Anti-Alzheimer AgentsNovel Tacrine-8-Hydroxyquinoline Hybrids as Mu

    11、ltifunctional Agents for the Treatment of Alzheimers Disease,with Neuroprotective,Cholinergic,Antioxidant,and Copper-Complexing Properties8/3/2022198/3/202220Bivalent-Carbolines as Potential Multitarget Anti-Alzheimer Agents8/3/202221AD modelvA platform to perform pharmacological evaluation of anima

    12、l models of Alzheimers diseasevIn the future drug candidates may be directly used to animal models of Alzheimers disease8/3/202222Further explore the causesThe brain of AD patient likes a labyrinth 8/3/202223CooperationvWhile each of us is running into a stone wall with Alzheimers,what will we do ne

    13、xt?vAllow researchers to study a larger pool of patients will help us see how the disease progresses,identify subgroups,and hopefully develop more sophisticated computer models that could save time and money developing drugs.8/3/2022244 PerspectivevWhile it is not possible to predict the success of

    14、any individual program,one or more are likely to prove effective.vDespite disappointing results from recently completed Phase III trials of several novel compounds,the extent and breadth of activity at all phases of clinical development suggest that new pharmacotherapeutic options for the treatment

    15、of AD will become available within the next decade.vIt seems reasonable to predict that in the not-too-distant future,a synergistic combination of agents will have the capacity to alter the neurodegenerative cascade and reduce the global impact of this devastating disease.8/3/202226Reference1 Michae

    16、l S Rafii and Paul S Aisen.Recent developments in Alzheimers disease therapeutics.BMC Medicine 2009,7:7,1741-7-15.2 Yvonne Rook.Bivalent-Carbolines as Potential Multitarget Anti-Alzheimer Agents.J.Med.C.XXXX,Vol.XXX,NO.XX3 Mara Isabel Fern andez-Bachiller.Novel Tacrine-8-Hydroxyquinoline Hybrids as

    17、Multifunctional Agents for the Treatment of Alzheimers Disease,with Neuroprotective,Cholinergic,Antioxidant,and Copper-Complexing Properties.J.Med.C.XXXX,XXX,000-000.4 Raymond T.Bartus&Reginald L.Dean III.Pharmaceutical treatment for cognitive deficits in Alzheimers disease and other neurodegenerati

    18、ve conditions:exploring new territory using traditional tools and established maps.Psychopharmacology(2009)202:1536.5 Marwan N.Sabbagh.Drug Development for Alzheimers Disease:Where Are We Now and Where Are We Headed?.The American Journal of Geriatric Pharmacotherapy 2009,7(3):167-185.6 Martin Citron.Alzheimers disease:strategies for disease modification.Nature Reviews.2010.7:387-398

    展开阅读全文
    提示  163文库所有资源均是用户自行上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作他用。
    关于本文
    本文标题:早老性痴呆药物研究进展课件.ppt
    链接地址:https://www.163wenku.com/p-3419705.html

    Copyright@ 2017-2037 Www.163WenKu.Com  网站版权所有  |  资源地图   
    IPC备案号:蜀ICP备2021032737号  | 川公网安备 51099002000191号


    侵权投诉QQ:3464097650  资料上传QQ:3464097650
       


    【声明】本站为“文档C2C交易模式”,即用户上传的文档直接卖给(下载)用户,本站只是网络空间服务平台,本站所有原创文档下载所得归上传人所有,如您发现上传作品侵犯了您的版权,请立刻联系我们并提供证据,我们将在3个工作日内予以改正。

    163文库